Last 12 months
Inside the activity.
41 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 3 | 2 |
| Jun 2026 | 17 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 10 | 1 |
| Sep 2026 | 11 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 441,468 | Not disclosed Strike: $10.48 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 15 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 441,468 shares Expires 2027-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
GrantShare Appreciation Rights C · Derivative | 245,654 | Not disclosed Strike: $20.03 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 14 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,654 Underlying: Class C Common Shares · 245,654 shares Expires 2029-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 245,654 | Not disclosed Strike: $20.03 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 13 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 245,654 shares Expires 2026-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
GrantShare Appreciation Rights C · Derivative | 231,480 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 12 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,480 Underlying: Class C Common Shares · 231,480 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 231,480 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 11 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 231,480 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
GrantShare Appreciation Rights C · Derivative | 400,000 | Not disclosed Strike: $21.39 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 10 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Class C Common Shares · 400,000 shares Expires 2028-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 400,000 | Not disclosed Strike: $21.39 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 9 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 400,000 shares Expires 2025-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
GrantShare Appreciation Rights A · Derivative | 220,734 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 8 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,734 Underlying: Class A Common Shares · 220,734 shares Expires 2030-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 220,734 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 7 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 220,734 shares Expires 2027-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
GrantShare Appreciation Rights A · Derivative | 122,827 | Not disclosed Strike: $19.91 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 6 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,827 Underlying: Class A Common Shares · 122,827 shares Expires 2029-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 122,827 | Not disclosed Strike: $19.91 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 5 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 122,827 shares Expires 2026-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
GrantShare Appreciation Rights A · Derivative | 115,740 | Not disclosed Strike: $18.63 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 4 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,740 Underlying: Class A Common Shares · 115,740 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 115,740 | Not disclosed Strike: $18.63 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 3 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 115,740 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
GrantShare Appreciation Rights A · Derivative | 200,000 | Not disclosed Strike: $21.58 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 2 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Shares · 200,000 shares Expires 2028-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
Nair BalanDirector · President and CEO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 200,000 | Not disclosed Strike: $21.58 | Not disclosed |
DisclosureSEC source: 0001712184-24-000239 · wk-form4_1729800377.xml · derivative · entry 1 Nair Balan · CIK 0001398905 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 200,000 shares Expires 2025-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
GrantShare Appreciation Rights C · Derivative | 37,356 | Not disclosed Strike: $10.48 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 12 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,356 Underlying: Class C Common Shares · 37,356 shares Expires 2030-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 37,356 | Not disclosed Strike: $10.48 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 11 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 37,356 shares Expires 2027-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
GrantShare Appreciation Rights C · Derivative | 20,766 | Not disclosed Strike: $20.03 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 10 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,766 Underlying: Class C Common Shares · 20,766 shares Expires 2029-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 20,766 | Not disclosed Strike: $20.03 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 9 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 20,766 shares Expires 2026-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
GrantShare Appreciation Rights C · Derivative | 21,218 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 8 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,218 Underlying: Class C Common Shares · 21,218 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 21,218 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 7 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 21,218 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
GrantShare Appreciation Rights A · Derivative | 18,678 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 6 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,678 Underlying: Class A Common Shares · 18,678 shares Expires 2030-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
Disposition to issuerShare Appreciation Rights A · Derivative | 18,678 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 5 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 18,678 shares Expires 2027-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
GrantShare Appreciation Rights A · Derivative | 10,383 | Not disclosed Strike: $19.91 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 4 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,383 Underlying: Class A Common Shares · 10,383 shares Expires 2029-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
Disposition to issuerShare Appreciation Rights A · Derivative | 10,383 | Not disclosed Strike: $19.91 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 3 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 10,383 shares Expires 2026-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
GrantShare Appreciation Rights A · Derivative | 10,609 | Not disclosed Strike: $18.63 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 2 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,609 Underlying: Class A Common Shares · 10,609 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:08 UTC |
ZOOK BRIAN DMD, CHIEF ACCOUNTING OFFICER
|
Disposition to issuerShare Appreciation Rights A · Derivative | 10,609 | Not disclosed Strike: $18.63 | Not disclosed |
DisclosureSEC source: 0001712184-24-000242 · wk-form4_1729800501.xml · derivative · entry 1 ZOOK BRIAN D · CIK 0001725076 · MD, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 10,609 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
GrantShare Appreciation Rights C · Derivative | 84,898 | Not disclosed Strike: $10.48 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 16 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,898 Underlying: Class C Common Shares · 84,898 shares Expires 2030-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
Disposition to issuerShare Appreciation Rights C · Derivative | 84,898 | Not disclosed Strike: $10.48 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 15 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 84,898 shares Expires 2027-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
GrantShare Appreciation Rights C · Derivative | 47,242 | Not disclosed Strike: $20.03 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 14 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,242 Underlying: Class C Common Shares · 47,242 shares Expires 2029-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
Disposition to issuerShare Appreciation Rights C · Derivative | 47,242 | Not disclosed Strike: $20.03 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 13 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 47,242 shares Expires 2026-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
GrantShare Appreciation Rights C · Derivative | 48,224 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 12 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,224 Underlying: Class C Common Shares · 48,224 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
Disposition to issuerShare Appreciation Rights C · Derivative | 48,224 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 11 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 48,224 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
GrantShare Appreciation Rights C · Derivative | 23,708 | Not disclosed Strike: $21.39 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 10 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,708 Underlying: Class C Common Shares · 23,708 shares Expires 2028-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
Disposition to issuerShare Appreciation Rights C · Derivative | 23,708 | Not disclosed Strike: $21.39 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 9 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 23,708 shares Expires 2025-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
GrantShare Appreciation Rights A · Derivative | 42,449 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 8 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,449 Underlying: Class A Common Shares · 42,449 shares Expires 2030-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
Disposition to issuerShare Appreciation Rights A · Derivative | 42,449 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 7 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 42,449 shares Expires 2027-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
GrantShare Appreciation Rights A · Derivative | 23,621 | Not disclosed Strike: $19.91 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 6 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,621 Underlying: Class A Common Shares · 23,621 shares Expires 2029-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
Disposition to issuerShare Appreciation Rights A · Derivative | 23,621 | Not disclosed Strike: $19.91 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 5 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 23,621 shares Expires 2026-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
GrantShare Appreciation Rights A · Derivative | 24,112 | Not disclosed Strike: $18.63 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 4 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,112 Underlying: Class A Common Shares · 24,112 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
Disposition to issuerShare Appreciation Rights A · Derivative | 24,112 | Not disclosed Strike: $18.63 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 3 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 24,112 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
GrantShare Appreciation Rights A · Derivative | 11,854 | Not disclosed Strike: $21.58 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 2 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,854 Underlying: Class A Common Shares · 11,854 shares Expires 2028-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:07 UTC |
WINTER JOHN MSVP, CLO AND SECRETARY
|
Disposition to issuerShare Appreciation Rights A · Derivative | 11,854 | Not disclosed Strike: $21.58 | Not disclosed |
DisclosureSEC source: 0001712184-24-000241 · wk-form4_1729800456.xml · derivative · entry 1 WINTER JOHN M · CIK 0001724412 · SVP, CLO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 11,854 shares Expires 2025-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
NOYES CHRISTOPHER JSVP, CHIEF FINANCIAL OFFICER
|
GrantShare Appreciation Rights C · Derivative | 101,878 | Not disclosed Strike: $10.48 | Not disclosed |
DisclosureSEC source: 0001712184-24-000240 · wk-form4_1729800411.xml · derivative · entry 16 NOYES CHRISTOPHER J · CIK 0001725072 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,878 Underlying: Class C Common Shares · 101,878 shares Expires 2030-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
NOYES CHRISTOPHER JSVP, CHIEF FINANCIAL OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 101,878 | Not disclosed Strike: $10.48 | Not disclosed |
DisclosureSEC source: 0001712184-24-000240 · wk-form4_1729800411.xml · derivative · entry 15 NOYES CHRISTOPHER J · CIK 0001725072 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 101,878 shares Expires 2027-03-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
NOYES CHRISTOPHER JSVP, CHIEF FINANCIAL OFFICER
|
GrantShare Appreciation Rights C · Derivative | 56,690 | Not disclosed Strike: $20.03 | Not disclosed |
DisclosureSEC source: 0001712184-24-000240 · wk-form4_1729800411.xml · derivative · entry 14 NOYES CHRISTOPHER J · CIK 0001725072 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,690 Underlying: Class C Common Shares · 56,690 shares Expires 2029-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
NOYES CHRISTOPHER JSVP, CHIEF FINANCIAL OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 56,690 | Not disclosed Strike: $20.03 | Not disclosed |
DisclosureSEC source: 0001712184-24-000240 · wk-form4_1729800411.xml · derivative · entry 13 NOYES CHRISTOPHER J · CIK 0001725072 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 56,690 shares Expires 2026-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
NOYES CHRISTOPHER JSVP, CHIEF FINANCIAL OFFICER
|
GrantShare Appreciation Rights C · Derivative | 57,870 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0001712184-24-000240 · wk-form4_1729800411.xml · derivative · entry 12 NOYES CHRISTOPHER J · CIK 0001725072 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,870 Underlying: Class C Common Shares · 57,870 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
NOYES CHRISTOPHER JSVP, CHIEF FINANCIAL OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 57,870 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0001712184-24-000240 · wk-form4_1729800411.xml · derivative · entry 11 NOYES CHRISTOPHER J · CIK 0001725072 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Common Shares · 57,870 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 20:06 UTC |
NOYES CHRISTOPHER JSVP, CHIEF FINANCIAL OFFICER
|
GrantShare Appreciation Rights C · Derivative | 23,708 | Not disclosed Strike: $21.39 | Not disclosed |
DisclosureSEC source: 0001712184-24-000240 · wk-form4_1729800411.xml · derivative · entry 10 NOYES CHRISTOPHER J · CIK 0001725072 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,708 Underlying: Class C Common Shares · 23,708 shares Expires 2028-01-02 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.